What is iRadimed's cash & equivalents?

iRadimed (IRMD) reported cash & equivalents of $56.37M in Q1 2026.

How has iRadimed's cash & equivalents changed year-over-year?

iRadimed's cash & equivalents increased by 12.0% year-over-year, from $50.33M to $56.37M.

What is the long-term trend for iRadimed's cash & equivalents?

Over 5 years (2020 to 2025), iRadimed's cash & equivalents has grown at a 0.4% compound annual growth rate (CAGR), from $50.07M to $51.16M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

iRadimed IRMD Cash & Equivalents

Cash & Equivalents at other companies

Merit Medical SystemsMMSI

$488.08M+23.4%

ICU MedicalICUI

$288.33M-0.5%

ITG

Integer HoldingsITGR

$8.12M-74.4%

Lumexa Imaging Holdings, Inc. LMRI

$51.23M—

RadNetRDNT

$455.34M-36.5%

iRhythm Holdings, Inc. IRTC

$248.5M-35.2%

Other financials

Income statement

See full

Revenue$22.0M+12.6%

Gross profit$16.8M+13.3%

Operating income$7.2M+33.2%

Net income$5.8M+24.1%

EPS (diluted)$0.45+21.6%

Balance sheet

See full

Total debt$59.2K-96.9%

Total equity$98.5M+9.4%

Total assets$114.4M+12.4%

Cash flow

See full

Operating cash flow$8.3M+93.2%

CapEx$403.0K-89.1%

Free cash flow$7.9M+1,226%

Valuation

See full

Market cap$1.21B+63.4%

P/E51.3×+13.8×

P/S14×+4.2×

Profitability

See full

Gross margin76.8%-0.1pp

Operating margin32.4%+2.3pp

Net margin27.4%+1.0pp

FCF margin28.4%+8.9pp

Returns & leverage

See full

Return on equity25%+1.2pp

Debt / equity0×0.0×

Current ratio7.1×-1.7×

Where this comes from

Reported directly by iRadimed in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: iRadimed’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRadimed's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is iRadimed's cash & equivalents?: iRadimed (IRMD) reported cash & equivalents of $56.37M in Q1 2026.
How has iRadimed's cash & equivalents changed year-over-year?: iRadimed's cash & equivalents increased by 12.0% year-over-year, from $50.33M to $56.37M.
What is the long-term trend for iRadimed's cash & equivalents?: Over 5 years (2020 to 2025), iRadimed's cash & equivalents has grown at a 0.4% compound annual growth rate (CAGR), from $50.07M to $51.16M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.